

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

November 8, 2017  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

---

**State of New York**  
(State of Other Jurisdiction  
of Incorporation)

**1-10113**  
(Commission File Number)

**11-0853640**  
(I.R.S. Employer  
Identification Number)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On November 8, 2017, we held our Annual Meeting of Shareholders at which the shareholders voted (i) for the election of Immanuel Thangaraj, Bruce F. Wesson, Robert B. Jones, William G. Skelly and George K. Ross to our Board of Directors for one-year terms; (ii) for an advisory resolution to approve executive compensation; (iii) for an advisory resolution setting the frequency of the vote to approve executive compensation at three years; (iv) for the adoption of the 2017 Restricted Stock Unit Award Plan; and (v) for the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2017 fiscal year ending December 31, 2017.

The results of the voting with respect to each matter voted upon, as applicable, are set forth below.

## 1. Election of Directors:

| <u>Nominee</u>     | <u>For</u> | <u>Withheld</u> | <u>Broker<br/>Non-Votes</u> |
|--------------------|------------|-----------------|-----------------------------|
| Robert B. Jones    | 11,251,595 | 602,245         | 4,902,130                   |
| Bruce F. Wesson    | 11,274,959 | 578,881         | 4,902,130                   |
| William Skelly     | 11,282,024 | 571,816         | 4,902,130                   |
| Immanuel Thangaraj | 11,280,171 | 573,669         | 4,902,130                   |
| George Ross        | 11,276,211 | 577,629         | 4,902,130                   |

## 2. Advisory Resolution Approving Executive Compensation

| <u>For</u> | <u>Against</u> | <u>Abstentions</u> | <u>Broker<br/>Non-Votes</u> |
|------------|----------------|--------------------|-----------------------------|
| 11,214,235 | 621,846        | 17,759             | 4,902,130                   |

## 3. Advisory Resolution On Frequency of Vote on Executive Compensation

| <u>One Year</u> | <u>Two Years</u> | <u>Three Years</u> | <u>Abstentions</u> | <u>Broker<br/>Non-Votes</u> |
|-----------------|------------------|--------------------|--------------------|-----------------------------|
| 649,512         | 53,991           | 11,135,660         | 14,677             | 4,902,130                   |

---

4. Adoption of the 2017 Restricted Stock Unit Award Plan

| <u>For</u> | <u>Against</u> | <u>Abstentions</u> | <u>Broker<br/>Non-Votes</u> |
|------------|----------------|--------------------|-----------------------------|
| 11,179,575 | 655,852        | 18,413             | 4,902,130                   |

5. Ratification of Independent Registered Public Accounting Firm for 2017 Fiscal Year:

| <u>For</u> | <u>Against</u> | <u>Abstentions</u> | <u>Broker<br/>Non-Votes</u> |
|------------|----------------|--------------------|-----------------------------|
| 16,477,177 | 233,766        | 45,027             | 0                           |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens

Peter A. Clemens

Senior Vice President & Chief Financial Officer

Date: November 8, 2017

---